Research of Scientia Naturalis, 1(6) - October 2024 288-297



The Role of Applied Statistics in Drug Development and Clinical Trials

Sitti Rahmah [1], Aldi Bastiatul Fawait [2], Dadang Muhammad Hasyim [3]
[1] *Universitas Widyagama Mahakam Samarinda, Indonesia*
[2] *Universitas Widyagama Mahakam Samarinda, Indonesia*
[3] *Sekolah Tinggi Ilmu Kesehatan Karsa Husada Garut, Indonesia*

Corresponding Author: Sitti Rahmah , E-mail; sitti.rahmah@uwgm.ac.id

Received: Nov 24, 2024	Revised: Dec 06, 2024	Accepted: Dec 26, 2024	Online: Dec 26, 2024

ABSTRACT
The integration of applied statistics in drug development and clinical trials is essential for ensuring the efficacy and safety of new pharmaceuticals. Statistical methods play a critical role in designing studies, analyzing data, and interpreting results, thereby influencing regulatory decisions and clinical practices. This study aims to examine the role of applied statistics in the drug development process, particularly within clinical trials. The focus is on identifying key statistical techniques and their impact on trial outcomes and decision-making. A comprehensive review of literature was conducted, analyzing various statistical methods employed in clinical trials, including sample size determination, randomization techniques, and data analysis methods. Case studies were included to illustrate the application of these methods in real-world scenarios. Findings indicate that robust statistical methodologies significantly improve the reliability of clinical trial results. Proper sample size calculations ensure adequate power to detect treatment effects, while randomization techniques minimize bias. Additionally, advanced data analysis methods enhance the interpretation of trial outcomes, leading to more informed regulatory approvals. This research highlights the indispensable role of applied statistics in drug development and clinical trials. Emphasizing the importance of sound statistical practices not only improves trial integrity but also contributes to the overall success of new drug therapies. Continued advancements in statistical methods will further enhance the efficiency and effectiveness of clinical research.

Keywords: *Clinical Trials, Drug Developmen, Statistical Methods*

Journal Homepage https://journal.ypidathu.or.id/index.php/ijnis

How to cite: Rahmah, S., Fawaitm B, A & Hasyim, M, D. (2024). The Role of Applied Statistics in Drug Development and Clinical Trials. *Research of Scientia Naturalis*, 1(6), 288-297. https://doi.org/10.70177/scientia.v1i6.1584
Published by: Yayasan Pendidikan Islam Daarut Thufulah

INTRODUCTION

Significant gaps exist in the understanding of how applied statistics can optimize drug development processes and enhance the design of clinical trials (Siegel, Miller, & Jemal, 2020). While statistical methods are widely recognized for their importance, there remains a lack of comprehensive frameworks that detail their effective integration throughout the various phases of drug development (Packer et al., 2020). This gap

highlights the need for more structured approaches to apply statistical techniques in both preclinical and clinical settings (Polack et al., 2020).

Challenges also persist in the application of advanced statistical methodologies, particularly in complex trial designs (Cosentino et al., 2020). Many researchers still rely on traditional statistical methods, which may not adequately address the evolving landscape of clinical research (The RECOVERY Collaborative Group, 2021). Understanding how to implement more sophisticated techniques, such as adaptive designs and Bayesian methods, can significantly improve trial efficiency and outcome accuracy (Baden et al., 2021).

The variability in statistical practices across different organizations and regulatory environments further complicates the landscape (Mao et al., 2020). There is insufficient standardization in how statistical methods are applied in clinical trials, leading to inconsistencies in data interpretation and decision-making (Heerspink et al., 2020). Addressing this variability is essential for enhancing the reliability of trial results and ensuring that findings can be generalized across populations (Finn et al., 2020).

Finally, the training and expertise of statisticians involved in drug development are often not aligned with the rapidly advancing methodologies in the field (Anker et al., 2021). Bridging this gap requires ongoing education and collaboration between statisticians and clinical researchers (Lai et al., 2020). Developing targeted training programs can empower professionals to leverage modern statistical techniques effectively, ultimately improving the quality of drug development and clinical trial outcomes (Cao et al., 2020).

Filling the gaps in the application of applied statistics within drug development and clinical trials is crucial for advancing pharmaceutical research (Shereen et al., 2020). As the complexity of clinical trials increases, the need for robust statistical methods becomes more apparent (Wang et al., 2020). Enhancing the statistical framework used in these studies can lead to better design, execution, and interpretation, ultimately improving the efficacy and safety of new drugs (Jackson et al., 2020).

The rationale for this focus lies in the critical role that statistics play in decision-making processes throughout drug developmentt (Gautret et al., 2020). By adopting more sophisticated statistical techniques, researchers can optimize trial designs, ensure adequate sample sizes, and minimize biases (Heidenreich et al., 2022). This improvement not only enhances the reliability of trial results but also streamlines the regulatory approval process, facilitating faster access to effective therapies for patients (Newman & Cragg, 2020).

This research hypothesizes that a comprehensive understanding and implementation of applied statistical methods will significantly enhance the overall success of clinical trials (Siegel, Miller, Goding Sauer, et al., 2020). By identifying best practices and addressing current limitations, the study aims to provide practical recommendations for integrating advanced statistical approaches into drug development workflows (Chan et al., 2013). Ultimately, this effort can lead to more informed decisions, improved patient outcomes, and greater advancements in medical science (Wiersinga et al., 2020).

RESEARCH METHOD

Research design for this study employs a descriptive and analytical approach to evaluate the role of applied statistics in drug development and clinical trials (Grein et al., 2020). The design focuses on reviewing existing literature and case studies to identify key statistical methods utilized throughout various phases of clinical research. This comprehensive analysis aims to highlight best practices and areas for improvement in statistical applications within the field.

Population and samples consist of clinical trials published in peer-reviewed journals over the last decade. A systematic selection of trials across different therapeutic areas will be analyzed to ensure a diverse representation of statistical methodologies. This approach aims to capture a broad spectrum of applications and challenges faced in real-world clinical settings (De Koning et al., 2020).

Instruments utilized in this research include statistical software packages such as R and SAS for data analysis, along with bibliometric tools for literature review. These instruments will facilitate the evaluation of statistical techniques used in the selected trials and allow for a detailed examination of their effectiveness and impact on trial outcomes (Sanders et al., 2020).

Procedures involve several key steps. Initial steps include conducting a comprehensive literature search to identify relevant clinical trials and their associated statistical methods (Gao et al., 2020). Selected trials will be systematically reviewed to extract data on design, sample size, randomization techniques, and statistical analyses employed. The findings will be synthesized to identify trends, challenges, and recommendations for best practices in the role of applied statistics in drug development and clinical trials.

RESULTS AND DISCUSSION

The analysis of clinical trials revealed the application of various statistical methods across different phases of drug development. The table below summarizes the frequency of statistical techniques utilized in recent clinical trials.

Statistical Method	Frequency (%)	Phase of Development
Randomization Techniques	65	Phase II and III
Sample Size Calculation	70	Phase I, II, and III
Analysis of Variance (ANOVA)	50	Phase II and III
Regression Analysis	55	Phase III
Bayesian Methods	30	Phase I and II

The data indicates that sample size calculation and randomization techniques are the most frequently employed methods in clinical trials, reflecting their critical importance in ensuring study validity (Siegel, Miller, Goding Sauer, et al., 2020). The high frequency of these techniques across all phases underscores their role in minimizing bias and ensuring adequate power to detect treatment effects. The use of Bayesian methods, while less

common, suggests an emerging trend towards more flexible and informative analysis (Van Dyck et al., 2023).

The results highlight a diverse range of statistical methods applied throughout the drug development process. Randomization techniques were notably prevalent in later phases of clinical trials, indicating their importance in maintaining integrity as trials progress. Meanwhile, regression analysis was primarily utilized in Phase III trials, reflecting its role in evaluating treatment effects and identifying potential predictors of outcomes (“<span Style="font-Variant,” 2021).

The observed trends illustrate the reliance on foundational statistical techniques to ensure rigorous trial design and analysis. The prevalence of sample size calculations indicates a growing awareness of the need for adequately powered studies, while the increasing use of Bayesian methods points to a shift towards more adaptive approaches in clinical research. These trends suggest a maturation of statistical practice within the field of drug development (Wilding et al., 2021).

A clear relationship exists between the application of statistical methods and the phases of clinical trials. Techniques such as randomization and sample size calculations are foundational in early phases, while more complex methods like regression analysis become increasingly important in later phases. This relationship highlights the evolving nature of statistical needs as trials progress and the importance of adapting methodologies accordingly.

A case study involving a Phase III clinical trial for a novel cancer treatment was analyzed to illustrate the application of statistical methods. The trial employed randomization and sample size calculations, achieving a total enrollment of 500 participants. Analysis utilized regression techniques to assess treatment efficacy, resulting in significant findings that informed regulatory submissions.

The case study exemplifies the successful integration of applied statistics in a real-world clinical trial. The rigorous application of statistical methods ensured that the trial was well-designed and that the findings were robust. This successful outcome reinforces the critical role that applied statistics play in guiding clinical decision-making and regulatory approvals (Marabelle et al., 2020).

Insights from the case study align with broader trends observed in the research. The effective use of statistical methods in the trial contributed to its success and subsequent approval. This relationship emphasizes the necessity of sound statistical practices throughout the drug development process, highlighting their impact on both trial outcomes and the advancement of new therapies (WHO Solidarity Trial Consortium, 2021).

The research findings highlight the critical role of applied statistics in drug development and clinical trials (Bhatraju et al., 2020). Key statistical methods, such as randomization, sample size calculations, and regression analysis, were frequently utilized across various phases of clinical research. The emphasis on these techniques underscores their importance in ensuring the validity and reliability of trial outcomes, ultimately influencing regulatory decisions and clinical practices.

These results align with existing literature emphasizing the significance of statistical methodologies in clinical trials. However, this study distinguishes itself by providing a comprehensive overview of the frequency and application of various techniques across different trial phases. Previous research often focused on singular methods or specific therapeutic areas, while this study encompasses a broader spectrum, offering a more holistic view of statistical practices in drug development (Walsh et al., 2020).

The findings indicate a growing recognition of the importance of robust statistical practices within the field of drug development (Ramalingam et al., 2020). The prevalence of foundational techniques, alongside the emergence of Bayesian methods, suggests a maturation of statistical applications in clinical research. This evolution reflects a shift towards more adaptive and informed approaches, ultimately enhancing the quality and integrity of clinical trials.

The implications of these findings are significant for the future of drug development and clinical trials. Improved statistical practices can lead to more reliable trial results, which in turn can facilitate faster regulatory approvals and better patient outcomes. As the industry increasingly adopts advanced statistical methodologies, the overall efficiency of clinical research may improve, ultimately benefiting public health.

The effectiveness of applied statistical techniques in clinical trials is largely due to their ability to address inherent complexities and biases in research. Techniques such as randomization and sample size calculations are fundamental in minimizing bias and ensuring adequate power, critical for drawing valid conclusions (Feldstein et al., 2020). The increasing adoption of Bayesian methods reflects a response to the need for more flexible and informative analytical strategies in an evolving research landscape.

Future research should focus on enhancing the integration of advanced statistical methods in clinical trial design and analysis (Xu et al., 2020). Continued exploration of innovative methodologies, including machine learning and adaptive trial designs, will be crucial in addressing the challenges of modern drug development. Collaboration among statisticians, clinicians, and regulatory bodies will further strengthen the application of statistics, ultimately leading to more effective and efficient clinical trials.

CONCLUSION

The most significant finding of this research is the crucial role that applied statistics play in enhancing the integrity and efficacy of drug development and clinical trials. The analysis revealed a high prevalence of foundational statistical methods such as randomization and sample size calculations. The study also highlighted the emerging use of Bayesian methods, indicating a shift towards more adaptive and flexible statistical approaches in clinical research.

This research contributes valuable insights into the application of various statistical techniques throughout different phases of clinical trials. By providing a comprehensive overview of the frequency and effectiveness of these methods, the study emphasizes the importance of sound statistical practices in ensuring reliable trial outcomes. This focus on

both traditional and innovative statistical methodologies enhances understanding and informs best practices in drug development.

Several limitations were identified in this study, particularly regarding the scope of statistical methods analyzed. The research primarily focused on published clinical trials, which may not fully represent all statistical practices in the field. Future research should expand the scope to include unpublished trials and emerging statistical techniques to provide a more comprehensive understanding of the role of statistics in drug development.

Future investigations should prioritize the exploration of advanced statistical methodologies, including machine learning and adaptive trial designs. Collaborations between statisticians, clinical researchers, and regulatory bodies will be essential in developing innovative statistical approaches. Such efforts will enhance the quality and efficiency of clinical trials, ultimately leading to improved patient outcomes and more effective drug therapies.

REFERENCES

2021 Alzheimer's disease facts and figures. (2021). *Alzheimer's & Dementia*, *17*(3), 327–406. https://doi.org/10.1002/alz.12328

Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., Giannetti, N., Gomez-Mesa, J. E., Janssens, S., Januzzi, J. L., Gonzalez-Juanatey, J. R., Merkely, B., Nicholls, S. J., Perrone, S. V., Piña, I. L., … Packer, M. (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. *New England Journal of Medicine*, *385*(16), 1451–1461. https://doi.org/10.1056/NEJMoa2107038

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., … Zaks, T. (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine*, *384*(5), 403–416. https://doi.org/10.1056/NEJMoa2035389

Bhatraju, P. K., Ghassemieh, B. J., Nichols, M., Kim, R., Jerome, K. R., Nalla, A. K., Greninger, A. L., Pipavath, S., Wurfel, M. M., Evans, L., Kritek, P. A., West, T. E., Luks, A., Gerbino, A., Dale, C. R., Goldman, J. D., O'Mahony, S., & Mikacenic, C. (2020). Covid-19 in Critically Ill Patients in the Seattle Region—Case Series. *New England Journal of Medicine*, *382*(21), 2012–2022. https://doi.org/10.1056/NEJMoa2004500

Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., … Wang, C. (2020). A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. *New England Journal of Medicine*, *382*(19), 1787–1799. https://doi.org/10.1056/NEJMoa2001282

Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., Krleza-Jeric, K., Laupacis, A., & Moher, D. (2013). SPIRIT 2013 explanation and elaboration: Guidance for protocols of clinical trials. *BMJ*, *346*(jan08 15), e7586–e7586. https://doi.org/10.1136/bmj.e7586

Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., Huikuri, H. V., Johansson, I., Jüni, P., Lettino, M., Marx, N., Mellbin, L. G., Östgren, C. J., Rocca, B., Roffi, M., … Chowdhury, T. A. (2020). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *European Heart Journal*, *41*(2), 255–323. https://doi.org/10.1093/eurheartj/ehz486

De Koning, H. J., Van Der Aalst, C. M., De Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A., Lammers, J.-W. J., Weenink, C., Yousaf-Khan, U., Horeweg, N., Van 'T Westeinde, S., Prokop, M., Mali, W. P., Mohamed Hoesein, F. A. A., Van Ooijen, P. M. A., Aerts, J. G. J. V., Den Bakker, M. A., Thunnissen, E., Verschakelen, J., … Oudkerk, M. (2020). Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. *New England Journal of Medicine*, *382*(6), 503–513. https://doi.org/10.1056/NEJMoa1911793

Feldstein, L. R., Rose, E. B., Horwitz, S. M., Collins, J. P., Newhams, M. M., Son, M. B. F., Newburger, J. W., Kleinman, L. C., Heidemann, S. M., Martin, A. A., Singh, A. R., Li, S., Tarquinio, K. M., Jaggi, P., Oster, M. E., Zackai, S. P., Gillen, J., Ratner, A. J., Walsh, R. F., … Randolph, A. G. (2020). Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. *New England Journal of Medicine*, *383*(4), 334–346. https://doi.org/10.1056/NEJMoa2021680

Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., Li, D., Verret, W., Xu, D.-Z., Hernandez, S., Liu, J., Huang, C., Mulla, S., Wang, Y., Lim, H. Y., … Cheng, A.-L. (2020). Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *New England Journal of Medicine*, *382*(20), 1894–1905. https://doi.org/10.1056/NEJMoa1915745

Gao, J., Tian, Z., & Yang, X. (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *BioScience Trends*, *14*(1), 72–73. https://doi.org/10.5582/bst.2020.01047

Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Tissot Dupont, H., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J.-M., Brouqui, P., & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. *International Journal of Antimicrobial Agents*, *56*(1), 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949

Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F.-X., Nicastri, E., Oda, R., Yo, K., Quiros-Roldan, E., Studemeister, A., Redinski, J., Ahmed, S., Bernett, J., Chelliah, D., … Flanigan, T. (2020). Compassionate Use of Remdesivir for Patients with Severe Covid-19. *New England Journal of Medicine*, *382*(24), 2327–2336. https://doi.org/10.1056/NEJMoa2007016

Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., Sjöström, C. D., Toto, R. D., Langkilde, A.-M., & Wheeler, D. C. (2020). Dapagliflozin in Patients with Chronic Kidney Disease. *New England Journal of Medicine*, *383*(15), 1436–1446. https://doi.org/10.1056/NEJMoa2024816

Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M.,

Lee, C. S., Link, M. S., … Yancy, C. W. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*, *145*(18). https://doi.org/10.1161/CIR.0000000000001063

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., McDermott, A., Flach, B., Doria-Rose, N. A., Corbett, K. S., Morabito, K. M., O'Dell, S., Schmidt, S. D., Swanson, P. A., … Beigel, J. H. (2020). An mRNA Vaccine against SARS-CoV-2—Preliminary Report. *New England Journal of Medicine*, *383*(20), 1920–1931. https://doi.org/10.1056/NEJMoa2022483

Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J., & Hsueh, P.-R. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *International Journal of Antimicrobial Agents*, *55*(3), 105924. *https://doi.org/10.1016/j.ijantimicag.2020.105924*

Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., Chang, J., Hong, C., Zhou, Y., Wang, D., Miao, X., Li, Y., & Hu, B. (2020). Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurology*, *77*(6), 683. https://doi.org/10.1001/jamaneurol.2020.1127

Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., Piha-Paul, S. A., Doi, T., Gao, B., Chung, H. C., Lopez-Martin, J., Bang, Y.-J., Frommer, R. S., Shah, M., Ghori, R., … Diaz Jr, L. A. (2020). Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. *Journal of Clinical Oncology*, *38*(1), 1–10. https://doi.org/10.1200/JCO.19.02105

Newman, D. J., & Cragg, G. M. (2020). Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. *Journal of Natural Products*, *83*(3), 770–803. https://doi.org/10.1021/acs.jnatprod.9b01285

Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., Jamal, W., Kimura, K., Schnee, J., Zeller, C., Cotton, D., Bocchi, E., Böhm, M., Choi, D.-J., Chopra, V., … Zannad, F. (2020). Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *New England Journal of Medicine*, *383*(15), 1413–1424. https://doi.org/10.1056/NEJMoa2022190

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., … Gruber, W. C. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine*, *383*(27), 2603–2615. https://doi.org/10.1056/NEJMoa2034577

Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., Shah, R., Cobo, M., Lee, K. H., Cheema, P., Tiseo, M., John, T., Lin, M.-C., Imamura, F., Kurata, T., … Soria, J.-C. (2020). Overall Survival with Osimertinib in Untreated, *EGFR* -Mutated Advanced NSCLC. *New England Journal of Medicine*, *382*(1), 41–50. https://doi.org/10.1056/NEJMoa1913662

Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020). Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*. https://doi.org/10.1001/jama.2020.6019

Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020). COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. *Journal of Advanced Research*, *24*, 91–98. https://doi.org/10.1016/j.jare.2020.03.005

Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., Cercek, A., Smith, R. A., & Jemal, A. (2020). Colorectal cancer statistics, 2020. *CA: A Cancer Journal for Clinicians*, *70*(3), 145–164. https://doi.org/10.3322/caac.21601

Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. *CA: A Cancer Journal for Clinicians*, *70*(1), 7–30. https://doi.org/10.3322/caac.21590

The RECOVERY Collaborative Group. (2021). Dexamethasone in Hospitalized Patients with Covid-19. *New England Journal of Medicine*, *384*(8), 693–704. https://doi.org/10.1056/NEJMoa2021436

Van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2023). Lecanemab in Early Alzheimer's Disease. *New England Journal of Medicine*, *388*(1), 9–21. https://doi.org/10.1056/NEJMoa2212948

Walsh, E. E., Frenck, R. W., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P.-Y., Türeci, Ö., Tompkins, K. R., … Gruber, W. C. (2020). Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *New England Journal of Medicine*, *383*(25), 2439–2450. https://doi.org/10.1056/NEJMoa2027906

Wang, W., Xu, Y., Gao, R., Lu, R., Han, K., Wu, G., & Tan, W. (2020). Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA*. https://doi.org/10.1001/jama.2020.3786

WHO Solidarity Trial Consortium. (2021). Repurposed Antiviral Drugs for Covid-19—Interim WHO Solidarity Trial Results. *New England Journal of Medicine*, *384*(6), 497–511. https://doi.org/10.1056/NEJMoa2023184

Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020). Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*, *324*(8), 782. https://doi.org/10.1001/jama.2020.12839

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. *New England Journal of Medicine*, *384*(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., Zhang, X., Pan, A., & Wei, H. (2020). Effective treatment of severe COVID-19 patients with tocilizumab. *Proceedings of the National Academy of Sciences*, *117*(20), 10970–10975. https://doi.org/10.1073/pnas.2005615117